Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PP-F11N and Sacubitril in Advanced Medullary Thyroid Cancer
NCT03647657Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Dec 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 177Lu-PP-F11N in medullary thyroid carcinoma (MTC) (2 arms), sponsored by University Hospital Basel. Primary endpoint: Tumor radiation doses at 72 hours. Started Dec 2018; status: completed.
02
Drugs
177Lu-PP-F11N
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT03647657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03647657.